Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01849952 : Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Phase
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion/Exclusion Criteria:

- 18 years of age

- Brain tumor(s) to be resected for clinical reasons.

- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III
or IV.

- Adequate tissue available for processing as determined by Pathology.

- Adequate decision making ability to review, discuss and sign a consent form to allow
their tumor samples to be used for future human brain tumor biology laboratory
research. Determination of capacity to consent is made by one of the co-investigators
based on clinical assessment.

- Patients opting for the standard treatment regimen for their disease as well as
ongoing clinical trials will be are eligible to participate in this study. Standard
care for newly-diagnosed glioblastomas typically consists of surgical resection
followed by radiotherapy with concomitant temozolomide, followed by adjuvant
temozolomide chemotherapy.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01849952      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740